TITLE

Imipramine in Treatment of Parkinsonism: a Double-blind Placebo Study

AUTHOR(S)
Strang, R. R.
PUB. DATE
July 1965
SOURCE
British Medical Journal;7/3/1965, Vol. 2 Issue 5452, p33
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
64059287

 

Related Articles

  • The pharmacotherapy of minor depression. Stewart, Jonathan W.; Quitkin, Frederic M. // American Journal of Psychotherapy;Jan1992, Vol. 46 Issue 1, p23 

    Presents assorted studies on the use of pharmacological treatments, ranging from placebo-controlled trials to open clinical ones, for minor depression. Definition of minor depression; Double-blind studies; Suggested treatment approach for minor depression; Fluoxetine; Imipramine.

  • Drug Treatment of Panic Disorder: Comparative Efficacy of Alprazolam, Imipramine, and Placebo. Klerman, Gerald L. // British Journal of Psychiatry;Feb92, Vol. 160, p191 

    The Cross-National Collaborative Panic Study, Phase Two, compared alprazolam with imipramine and with placebo in a sample of 1168 randomly assigned subjects. The study, conducted at 12 centres, assessed clinical change over eight weeks of double-blind drug treatment. Improvement occurred with...

  • Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: a double-blind, Placebo-controlled, randomized study. Safarinejad, M. R.; Taghva, A.; Shekarchi, B.; Safarinejad, Sh. // International Journal of Impotence Research;Mar/Apr2011, Vol. 23 Issue 2, p94 

    The article presents a retraction of the article "Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: a double-blind, Placebo controlled, randomized study," by M. R. Safarinejad to the "International Journal of Impotence Research."

  • Amgen's phase II study of GDNF fails to meet primary endpoint.  // PharmaWatch: Biotechnology;August 2004, Vol. 3 Issue 8, p8 

    Amgen Inc. has confirmed that the phase II study of its novel glial cell line-derived neurotrophic factor, or GDNF, for the treatment of advanced Parkinson's disease did not meet the primary study endpoint upon completion of six months of the double-blind treatment phase of the study. The phase...

  • A randomized controlled trial of imipramine in patients with irritable bowel syndrome. Abdul-Baki, Heitham; El Hajj, Ihab I.; ElZahabi, Lara; Azar, Cecilio; Aoun, Elie; Skoury, Assaad; Chaar, Hani; Sharara, Ala I. // World Journal of Gastroenterology;8/7/2009, Vol. 15 Issue 29, p3636 

    AIM: To study the efficacy of low-dose imipramine in relieving symptoms associated with the irritable bowel syndrome (IBS). METHODS: A randomized, double-blind trial of 25 mg imipramine vs matched placebo for 12 wk was performed. Doubling the dose was allowed once at week 2 in case of an...

  • Tolterodine and imipramine in refractory enuresis; a placebo-controlled crossover study. Nevéus, Tryggve; Tullus, Kjell // Pediatric Nephrology;Feb2008, Vol. 23 Issue 2, p263 

    The anticholinergic drug tolterodine has been suggested to be useful in therapy-resistant enuresis. Imipramine has a proven efficiency in unselected enuretic patients, but due to its side-effect profile it is only indicated, if at all, in therapy-resistant cases. We therefore compared these two...

  • Amgen's phase II study of GDNF fails to meet primary endpoint.  // PharmaWatch: CNS;August 2004, Vol. 3 Issue 8, p8 

    Amgen has confirmed that the phase II study of its novel glial cell line-derived neurotrophic factor, or GDNF, for the treatment of advanced Parkinson's disease did not meet the primary study endpoint upon completion of six months of the double-blind treatment phase of the study. The primary...

  • The predictive value of the dexamethasone suppression test. A placebo-controlled study. Peselow, Eric O.; Stanley, Michael; Filippi, Ann-Marie; Barouche, Faouzia; Goodnick, Paul; Fieve, Ronald R.; Peselow, E D; Stanley, M; Filippi, A M; Barouche, F; Goodnick, P; Fieve, R R // British Journal of Psychiatry;Nov89, Vol. 155, p667 

    We evaluated the dexamethasone suppression test (DST) as a predictor of response to drugs and placebo in 105 patients, in a large double-blind placebo-controlled out-patient trial to determine the efficacy of paroxetine HCl, a selective serotonin reuptake inhibitor, compared with that of...

  • Newron begins trial of safinamide in Parkinson's disease patients.  // PharmaWatch: CNS;October 2004, Vol. 3 Issue 10, p10 

    The article presents information about an Italian-based Newron Pharmaceuticals SpA, which has initiated an international clinical trial of its investigational product, safinamide, in 240 patients with Parkinson's disease. The placebo-controlled, 18-month, phase III trial will compare two dose...

  • Results from renowned "Study 329" called into question.  // Reactions Weekly;Oct2015, Vol. 1571 Issue 1, p9 

    The article discusses the reanalysis of "Study 329" which reveals that the efficacy of paroxetine and imipramine was not significantly different from placebo.

Share

Read the Article

Other Topics